<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189956</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-004</org_study_id>
    <nct_id>NCT00189956</nct_id>
  </id_info>
  <brief_title>Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.</brief_title>
  <official_title>Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to find the optimal dose for the smallpox candidate vaccine
      IMVAMUNE (MVA-BN). For this purpose the study compares IMVAMUNE (MVA-BN) administered at
      three different dose levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ELISA seroconversion rate</measure>
    <time_frame>Day 42</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA seroconversion rate</measure>
    <time_frame>Days 28, 84</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT</measure>
    <time_frame>Days 28, 42, 84</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT seroconversion rate</measure>
    <time_frame>Days 28, 42, 84</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT</measure>
    <time_frame>Days 28, 42, 84</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytotoxic T-Lymphocyte response</measure>
    <time_frame>Days 28, 42, 84</time_frame>
    <description>The Cytotoxic T-Lymphocyte (CTL) response was determined by measuring IFNγ producing cells by Intracellular cytokine staining (ICS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>within 12 weeks</time_frame>
    <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence and intensity of solicited local AEs. Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited General Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence of solicited general AEs: Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 31 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited non-serious AEs: Intensity and relationship to vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy, vaccinia naïve subjects
1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE (MVA-BN)</intervention_name>
    <description>Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects, aged 18 - 30 years

          -  Signed informed consent after being advised of the risks and benefits of the study in
             a language able to understand, and prior to performance of any study specific
             procedure.

          -  Free of obvious health problems with acceptable medical history by screening
             evaluation and physical examination.

          -  Subject of not of child-bearing potential or all of the following: A urine/serum ß-HCG
             pregnancy test gives a negative result, use of adequate contraceptive precautions for
             30 days before first vaccination.

        Exclusion Criteria:

          -  Known or suspected history of smallpox vaccination or typical vaccinia scar.

          -  Positive test result in MVA specific ELISA or PRNT at screening.

          -  Positive result in HIV or HCV antibody test at screening.

          -  HbsAG positive at screening.

          -  Pregnancy or breast-feeding.

          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy

          -  History of any serious medical condition, which in the opinion of the investigator,
             would compromise the safety of the subject.

          -  History of autoimmune disease

          -  History of malignancy.

          -  History of chronic alcohol abuse and/or intravenous drug abuse.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  History of anaphylaxis or severe allergic reaction.

          -  Acute disease (a moderate or severe illness with or without a fever) at the time of
             enrolment.

          -  Any vaccinations within a period starting 30 days prior to administration of the
             vaccine and ending at study conclusion.

          -  Chronic administration of immuno-suppressants or other immune-modifying drugs.

          -  Administration or planned administration of immunoglobulins and/or any blood products
             during the study period.

          -  Use of any investigational or non-registered drug or vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Pokorny, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Pharma Contract</name>
      <address>
        <city>Basel</city>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030. Epub 2009 Nov 25.</citation>
    <PMID>19944151</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

